ROSEN, A LEADING LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - May 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the 'Class Period'); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline.
SO WHAT: If you sold and/or held Cerevel common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Cerevel class action, go to https://rosenlegal.com/submit-form/?case_id=37997 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements in connection with Cerevel's October 16, 2023 secondary stock offering and in its January 18, 2024 proxy statement. As alleged in the complaint, the secondary stock offering was orchestrated by Cerevel's controlling shareholders, Bain Capital, LP and Pfizer Inc., to allow Bain to increase its position in Cerevel at a deeply discounted price in advance of AbbVie Inc.'s undisclosed forthcoming acquisition of Cerevel. Just 51 days after the offering, Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share - i.e., nearly double the offering price - and Bain's discounted purchases from the offering resulted in it receiving a windfall of more than $120 million. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Cerevel class action, go to https://rosenlegal.com/submit-form/?case_id=37997 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252469
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks
Investors have been hit with a great deal of volatility and uncertainty in the markets lately. Even so, these two companies are healthcare leaders that can still perform well. Both have solid growth prospects and have increased their payouts for a combined 101 years. 10 stocks we like better than Medtronic › Some stock-trading platforms enable their users to automatically replicate the positions taken by experienced investors or other famous figures. Many investors might prefer to do their own research before buying shares of a company, but it's still a good idea to pay attention to some of the moves more experienced names on Wall Street make. Take Ken Griffin, a successful money manager and the billionaire CEO of Citadel Advisors, the hedge fund he founded. During the first quarter, Griffin and his team made several moves that investors, including those seeking reliable dividend payers, should seriously consider copying. The hedge fund added shares of Medtronic (NYSE: MDT) and AbbVie (NYSE: ABBV). Here's why these two are top options for dividend seekers. Medtronic checks several of the boxes that dividend investors look to find. Let's consider three of them. First, the company develops and markets medical devices. As a leader in a defensive industry, Medtronic tends to perform better than most even in challenging conditions. The business is highly unlikely to go under, which means there is less risk of payout cuts. Medtronic's shares have performed slightly better than the S&P 500 this year -- despite significant volatility and fears of a recession -- while it continues to generate steady revenue and profits. That's precisely what income seekers want. Second, Medtronic has several important growth avenues. The company is inching closer to approval in the U.S. for its Hugo device, a robotic-assisted surgery (RAS) system, in urologic procedures. That will mark the device's grand commercial entrance into the U.S. market. Medtronic should seek label expansions for it in the future. The RAS industry appears to be significantly underpenetrated. As Medtronic pointed out two years ago, less than 5% of procedures that could be performed robotically currently are. The company's Hugo system will unlock massive long-term growth opportunities and help it continue delivering consistent financial results just as it has been doing. Third, Medtronic has an impeccable dividend track record, having grown its payouts for 48 consecutive years. Its 3.4% forward yield is above the S&P 500's average of 1.3%. Medtronic currently faces some challenges, including the threat of tariffs. It expects a net tariff hit of between $200 million and $350 million during its fiscal year 2026 (which just started). However, Medtronic is looking for ways to mitigate the impact of tariffs. For its fiscal 2026, it projected revenue growth of 5% year over year and adjusted earnings-per-share (EPS) growth of 1% at the midpoint, including the impact of tariffs. These trade developments will harm the company in the short term, but Medtronic should find ways to minimize the negative impact in the long term if these tariffs remain in place for an extended period, which is by no means certain. In my view, even with that threat, Medtronic remains a top stock to buy and hold for the long term, especially for dividend seekers. AbbVie's shares fell off a cliff in November after an otherwise promising pipeline program flopped in a phase 2 study. The drugmaker is no stranger to clinical setbacks. No pharmaceutical giant is. However, AbbVie's underlying business still looks incredibly solid. The company's revenue and earnings are growing at a good clip largely thanks to its two immunology superstars, Skyrizi and Rinvoq. Management expects these medicines to hit $31 billion in combined sales by 2027 (versus $17.7 billion last year). However, AbbVie's greatest strength isn't its current lineup of immunology medicines. It's the company's ability to overcome clinical setbacks and major patent cliffs by successfully developing newer and better medicines. Skyrizi and Rinvoq helped AbbVie move beyond Humira, its former top-selling medicine, which lost U.S. patent exclusivity in January 2023. Skyrizi and Rinvoq overlap with many of Humira's indications, sometimes with greater efficacy. AbbVie's deep pipeline should enable it to develop successors to its current crop of drugs even if it has to endure setbacks along the way. AbbVie's business is impressive and so is its dividend history. The company has increased its payouts for 53 consecutive years -- making it a Dividend King -- and currently offers a forward yield of 3.6%. AbbVie is an outstanding dividend stock despite the issues it has encountered in the past two years. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
A race against time: what now for Thames Water after rescue deal collapses?
Thames Water came close to collapse this year as it almost ran out of money. But after agreeing to exclusive takeover talks with the US private equity company KKR, the debt-laden utility was hoping for a quieter period as it sorted out the details. Those hopes were extinguished on Tuesday after KKR said it was withdrawing its bid – to the shock of Thames Water and its creditors. It is those creditors, some of whom bought Thames's debt at a big discount in the hope of a quick profit, who have been left – without warning – with the responsibility of pulling together billions of pounds to carry out a turnaround that could take 15 years. Related: Thames Water hit with £123m of fines over sewage and dividend breaches Thames Water has been through a tumultuous year already. It had a close shave with bankruptcy, a high court battle to secure £3bn in emergency investment, and several testy parliamentary hearings. It must invest £20bn over the next five years to fix leaking pipes and water treatment works, all while trying to fend off public anger over sewage in Britain's rivers and seas. KKR balked at the complexity of taking on Thames amid so much scrutiny and with multiple stakeholders in play, according to a person close to the talks. Partners at the private equity firm had carried out 10 weeks of intensive due diligence, including several visits to wastewater treatment works, and had relied on a small army of up to 200 advisers to carry out detailed assessments. The state of some of the Thames assets was worse than KKR had initially thought, according to another source. New York-based KKR, short for Kohlberg, Kravis Roberts, had deployed 15 members of its European infrastructure team, run by the executive Tara Davies, to work on the bid, with James Gordon serving as the lead partner. (Both formerly worked for Macquarie, the Australian investment bank criticised for taking dividends from Thames while building up debt – although they are not thought to have worked on the water company.) Yet over the weekend KKR brought out one of its big guns to try to sweet talk the government: Henry Kravis, one of the co-founders, called up Labour's business adviser Varun Chandra to discuss the plan. Sky News first reported the call. KKR has rarely been shy of potential controversy, ever since its infamous 1988 buyout of the US conglomerate RJR Nabisco was depicted in the book Barbarians at the Gate. However, several people close to the Thames Water situation have said they believed KKR also became concerned about the political risks associated with it, such as the possibility of intense public scrutiny leading to a stricter approach from the government on enforcement. A government spokesperson said: 'The government makes no apology for tackling the poor behaviour we have seen in the past, where too many people were rewarded for failure,' but added: 'We welcome investors who want to work with us to rebuild this vital sector and clean up our rivers, lakes and seas.' Ofwat, the water regulator for England and Wales, last week laid down the gauntlet to KKR with £123m in new penalties mostly related to environmental breaches involving sewage spills. KKR's bid hinged on convincing regulators including Ofwat and the Environment Agency to grant it leniency on fines, penalties and other costs amounting to billions of pounds, as revealed by the Guardian. 'There were always going to be three people in the marriage,' wrote Helen Rodriguez, the head of European special situations at CreditSights, a bond rating agency: Thames Water, KKR and Ofwat. KKR may have been put off by 'the inevitable drip of more fines to come', and decided it was not worth going through a month of meetings in June to try to reach a compromise, she added. Thames Water has hired its own army of advisers, including the law firm Linklaters. It is understood the Linklaters lawyers involved have included Alison Saunders, formerly the UK's director of public prosecutions, and Jonathan Jones, a former head of the government's legal department. Saunders has previously acted for Southern Water on a criminal investigation, while Jones acted for the energy company Bulb during its special administration. Linklaters declined to comment. Keir Starmer's office received a courtesy call from KKR before the announcement. The government is hoping to avoid involvement. The environment secretary, Steve Reed, told parliament on Tuesday there remained 'a market-led solution on the table' as he categorically ruled out a permanent nationalisation. However, Reed acknowledged that the government was ready to put Thames Water into a special administration regime – akin to a temporary nationalisation – if required. Yet the 'market-led solution' leaves the government with the prospect of the UK's biggest water company being owned by a group of creditors that includes US hedge funds – such as Elliott Investment Management and Silver Point Capital – which are known for controversial tactics, as well as big institutional investors such as Aberdeen, BlackRock, Invesco and M&G. It is an unwieldy group of 100 companies, holding £13bn in Thames Water bonds. The investment bank Jefferies is acting as the group's main financial adviser. Despite the financial pressure Thames is under – and the cash burn required to fund its operations – the water company has covered the costs of as much as £15m for due diligence checks that KKR spent on exploring the state of the vast business. Much of that information has already been shared with the creditor group, and will now be used to inform their talks with Ofwat. However, the creditors must race to secure a deal as Thames burns through the first £1.5bn of the emergency cash it borrowed to fund its day-to-day operations. Like KKR before it, the creditor group will also try to reach an accommodation with Ofwat that will reduce the scope for big fines that would threaten to wipe out their financial returns. The new owners would look to install a board with more water industry experience. The position of Thames Water's chief executive, Chris Weston, is unclear. 'The creditors believe that Thames Water requires an urgent and fundamental reset and there is a very short and closing window in which a market-led solution can succeed,' a spokesperson for the lenders said. 'Discussions with Ofwat and the government will be advanced in the coming weeks to reach an agreement and turnaround for the benefit of customers and the environment.' Even if yet another deal on Thames Water can be reached, people involved in the crisis noted the irony of the timing of KKR's decision: it was announced just as an interim government review highlighted 'deep-rooted, systemic' problems in England and Wales's privatised water industry. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
